dihexa fda approval Big news for peptides! In July, the will meet to evaluate the most commonly used peptides for FDA authorized compounding Dihexa (PNB-0408) | c-Met/HGFR Activator
Description
H., Reitz, R

The (clear) supernatant was transferred into regular 1.5ml tubes and spun again for 5min at 4.6 g

This localized action often results in a lower incidence of central nervous system-related side effects, making them appealing to a broader patient demographic

Timing: No strict timing requirement between the two